Who
Anthony Caggiano
Chief Medical Officer
Company insider
Files Form 4 as: Chief Medical Officer, Cognition Therapeutics.
In numbers
- Trades disclosed
- 24
- Buys
- 1
- Sells
- 0
- Bought
- $22K
- Sold
- $0
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 1 Nov 2021
- Last trade
- 16 Apr 2026
- Last filed
- 20 Apr 2026
Companies traded
Activity over time
1 Apr – 1 Oct
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 16 Apr 2026filed 20 Apr 2026 | CGTX Cognition TherapeuticsBiotechnology | SEC FORM 4 Bought | $11K10,000 at $1.11 | filing |
| 16 Apr 2026filed 20 Apr 2026 | CGTX Cognition TherapeuticsBiotechnology | SEC FORM 4 Bought | $11K10,000 at $1.11 | filing |
| 15 Feb 2026filed 18 Feb 2026 | CGTX Cognition TherapeuticsBiotechnology | SEC FORM 4 Code F | $5,2424,680 at $1.12 | filing |
| 15 Feb 2026filed 18 Feb 2026 | CGTX Cognition TherapeuticsBiotechnology | SEC FORM 4 Code F | $5,2424,680 at $1.12 | filing |
| 4 Feb 2026filed 5 Feb 2026 | CGTX Cognition TherapeuticsBiotechnology | SEC FORM 4 Code F | $28K26,919 at $1.03 | filing |
| 4 Feb 2026filed 5 Feb 2026 | CGTX Cognition TherapeuticsBiotechnology | SEC FORM 4 Code F | $28K26,919 at $1.03 | filing |
| 3 Feb 2026filed 5 Feb 2026 | CGTX Cognition TherapeuticsBiotechnology | SEC FORM 4 Code A | —400,000 at $0.00 | filing |
| 3 Feb 2026filed 5 Feb 2026 | CGTX Cognition TherapeuticsBiotechnology | SEC FORM 4 Code F | $13K11,488 at $1.12 | filing |
| 3 Feb 2026filed 5 Feb 2026 | CGTX Cognition TherapeuticsBiotechnology | SEC FORM 4 Code A | —400,000 at $0.00 | filing |
| 3 Feb 2026filed 5 Feb 2026 | CGTX Cognition TherapeuticsBiotechnology | SEC FORM 4 Code F | $13K11,488 at $1.12 | filing |
| 18 Dec 2025filed 22 Dec 2025 | CGTX Cognition TherapeuticsBiotechnology | SEC FORM 4 Code A | —65,000 at $0.00 | filing |
| 18 Dec 2025filed 22 Dec 2025 | CGTX Cognition TherapeuticsBiotechnology | SEC FORM 4 Code F | $30K20,280 at $1.50 | filing |
| 29 Jul 2025filed 31 Jul 2025 | CGTX Cognition TherapeuticsBiotechnology | SEC FORM 4 Code A | —65,000 at $0.00 | filing |
| 29 Jul 2025filed 31 Jul 2025 | CGTX Cognition TherapeuticsBiotechnology | SEC FORM 4 Code F | $14K20,281 at $0.67 | filing |
| 15 Feb 2025filed 18 Feb 2025 | CGTX Cognition TherapeuticsBiotechnology | SEC FORM 4 Code F | $3,1255,296 at $0.59 | filing |
| 4 Feb 2025filed 4 Feb 2025 | CGTX Cognition TherapeuticsBiotechnology | SEC FORM 4 Code A | —295,000 at $0.00 | filing |
| 3 Feb 2025filed 4 Feb 2025 | CGTX Cognition TherapeuticsBiotechnology | SEC FORM 4 Code F | $8,56212,779 at $0.67 | filing |
| 15 Feb 2024filed 20 Feb 2024 | CGTX Cognition Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —60,000 at $0.00 | filing |
| 15 Feb 2024filed 20 Feb 2024 | CGTX Cognition TherapeuticsBiotechnology | SEC FORM 4 Code A | —60,000 at $0.00 | filing |
| 3 Feb 2024filed 9 Feb 2024 | CGTX Cognition TherapeuticsBiotechnology | SEC FORM 4 Code F | $29K12,777 at $2.29 | filing |
News
Cognition Therapeutics (NASDAQ:CGTX) Stock Falls 2% – Here's WhyCGTX · dailypolitical.com · 10 Oct 2026
0 headlines in the last 90 days name Anthony Caggiano; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.